Just to say I was right this morning at 8 o'clock to say it was closed. didn't bother to argue the point but if you ever want to know what is being shorted Short Tracker isn't that good and can be as much as two days behind the FCA site.
Lots of news expected this quarter
Allthat errrr, 7th Oct, try finding it now, not posting a link to Wednesdays positions, nice try though.
Allthat, twaddle, it is no longer on any short tracker platform.
That's a very good start to the day :-)
Very possible now THE SHORT HAS BEEN CLOSED Yahooo!!!!!
Personally I am of the opinion that shorting any company should be banned, it is a very contentious issue and can be extremely damaging to any company whichever sector it is part of. It was only last year that there were calls from companies on the market to ban this practice and it may still be in discussion, but is the practice at its root simply theft? For me the answer is yes and the practice should be banned. There is more news expected this quarter lets hope it's soon and buries the Citadel short along with its client. American based and mucking about with our market, just ridiculous.
MAX, I hate to say it but you really have no idea do you? It just reinforces my earlier post that a lot of "investors" turned up here having NAC as to what news is expected in Q4 and I'm Fooked if I'm gonna tell ya, jeez, ere, ang on a minit Guv and I'll polish ya shoes. Learn to read and research is the best advice I can give you. "Does that mean I can't copy your answers for this test?" Yeh it does F#*kw@t. Kinell where do they birth them. are you the guy that mortgaged his house to "Dabble"? Good luck but if I were you I'd lay off the sauce mate.
For those not in the know this company is addressing multiple health issues not just Cancer and IBS, Autism Spectrum Disorder since 2015, Ulcerative Colitis since 2014 etc. etc. This is disruptive technology at work in medicine. The Oncology RNS was nothing short of spectacular and there can be no arguing that fact, so you can either be someone who believed Apple had something at the time or someone who sat around saying it would never catch on............coughs ever so slightly.
OPHID, NOT all gaps are filled in the sp trajectory, I would agree that most are (around 90%) but this is usually done as share movement stagnates and drops off due to lack of news, however this particular gap was as a result of the MM's gapping it up on open having digested the RNS on the 26th.regarding cancer treatment. A "natural" gap up, these gaps are rarely if ever filled when news is consistent and good, technically for the MM's it's very difficult to drag it back to fill that gap without it being engineered in some way and even the MM's on the AIM are careful not to overstep that particular line. They're in it to make money as risk free as possible not to fill gaps of their own making on good news.
MIKODX, it's meant to be, over 40% of LSE members arrived in March- April having never invested before in the AIM, you see them jump from board to board usually with lines like..."HI guys, new to this share but been looking in for a week or so, where do we see the sp going to? I wont hold you to it" ridiculous, farcical and it isn't an intelligent way to invest hard earned cash.
MIKODX, then why the hell do they buy into something they know absolutely nothing about and by implication have done absolutely no research on apart from a rising sp and a billboard, they should just stick with BET 365 or whatever.
Alot of people were basically mugged out of their shares yesterday, you only have to take a look at the 1,6 million shares bought in blocks ranging from 30-135k at a time for the last 2.5hrs of trading, I've not included any of the smaller buys under 30k. Total panic for absolutely no reason. Perhaps a sign of the times :-)
4D pharma announces topline results from Blautix® Phase II trial in irritable bowel syndrome (IBS)
Positive trends seen in primary efficacy endpoint of the study of overall response in both IBS-C and IBS-D subgroups
Statistically significant impact on overall response in combined IBS-C and IBS-D group
Blautix® was well tolerated, with a safety profile comparable to placebo
Phase II trial results provide strong foundation for the continued development of the first therapeutic with potential to treat both major subtypes of IBS. Bought a lot more, what's not to like?
The trial is conducted over various demographics whether they be age, occupation, habits etc. These are termed "cohorts", the positiveeffects of the therapy was virtually identical across each cohort, that is why it is termed as non significant. The treatment was effective across the whole demographic.
-"A positive, though non-significant, increase in overall response in both IBS-C and IBS-D cohorts; " is extremely positive if you know what cohort means in this context :-)
What a fantastic result for phase 2, undoubtedly going to be a game changer in treating this condition and a massive boost for 4D within the pharma industry, the sp is of course going vertical today.
IBS results in the first few days of Q4, "few" mmmmmm I'd say between Friday and next Wednesday , note to self...just keep buying as and when :-)
Get a grip ffs, nothing has changed since yesterday, jeez talk about wobblers, any dip or "opportunity" and "the sky is falling, the sky is falling" kinell, but thanks just added another reasonable amount at a ridiculously low price :-)